Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Scott Obach

Showing results (11-20 of 193) with videos related to

Pageof 20
Sort By:
Bioanalysis|March 14, 2014
Data-driven approach for cross-species comparative metabolite exposure assessment: how to establish fundamental bioanalytical parameters for the peak area ratio methodHongying Gao, R Scott Obach
Drug Metabolism and Pharmacokinetics|April 10, 2026
Advances in DDI evaluations: Recent trends from pre-clinical studies to regulatory submissionsChie Emoto, R Scott Obach
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 25, 2005
In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitudeKarthik Venkatakrishnan, R Scott Obach
The AAPS Journal|January 9, 2015
Addressing the challenges of low clearance in drug researchLi Di, R Scott Obach
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 30, 2012
A simple liquid chromatography-tandem mass spectrometry method to determine relative plasma exposures of drug metabolites across species for metabolite safety assessments (metabolites in safety testing). II. Application to unstable metabolitesHongying Gao, R Scott Obach
Drug Metabolism and Pharmacokinetics|January 6, 2026
Cytochrome P450 reaction phenotyping: State of the artElaine Tseng, R Scott Obach
Chemical Research in Toxicology|December 19, 2006
Metabolites and safety: What are the concerns, and how should we address them?Dennis A Smith, R Scott Obach
Chemical Research in Toxicology|January 27, 2009
Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatmentDennis A Smith, R Scott Obach
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 11, 2003
Verification of the selectivity of (+)N-3-benzylnirvanol as a CYP2C19 inhibitorRobert L Walsky, R Scott Obach
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 9, 2006
Metabolism of nomifensine to a dihydroisoquinolinium ion metabolite by human myeloperoxidase, hemoglobin, monoamine oxidase A, and cytochrome P450 enzymesR Scott Obach, Deepak K Dalvie
Pageof 20

Showing results (11-20 of 193) with videos related to

Sort By:
Pageof 20
Bioanalysis|March 14, 2014
Data-driven approach for cross-species comparative metabolite exposure assessment: how to establish fundamental bioanalytical parameters for the peak area ratio methodHongying Gao, R Scott Obach
Drug Metabolism and Pharmacokinetics|April 10, 2026
Advances in DDI evaluations: Recent trends from pre-clinical studies to regulatory submissionsChie Emoto, R Scott Obach
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 25, 2005
In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitudeKarthik Venkatakrishnan, R Scott Obach
The AAPS Journal|January 9, 2015
Addressing the challenges of low clearance in drug researchLi Di, R Scott Obach
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 30, 2012
A simple liquid chromatography-tandem mass spectrometry method to determine relative plasma exposures of drug metabolites across species for metabolite safety assessments (metabolites in safety testing). II. Application to unstable metabolitesHongying Gao, R Scott Obach
Drug Metabolism and Pharmacokinetics|January 6, 2026
Cytochrome P450 reaction phenotyping: State of the artElaine Tseng, R Scott Obach
Chemical Research in Toxicology|December 19, 2006
Metabolites and safety: What are the concerns, and how should we address them?Dennis A Smith, R Scott Obach
Chemical Research in Toxicology|January 27, 2009
Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatmentDennis A Smith, R Scott Obach
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 11, 2003
Verification of the selectivity of (+)N-3-benzylnirvanol as a CYP2C19 inhibitorRobert L Walsky, R Scott Obach
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 9, 2006
Metabolism of nomifensine to a dihydroisoquinolinium ion metabolite by human myeloperoxidase, hemoglobin, monoamine oxidase A, and cytochrome P450 enzymesR Scott Obach, Deepak K Dalvie
Pageof 20